Regulus Drug Candidate RG-012 to Treat Kidney Damage in Alport Patients Begins Phase 1 Clinical Trials
RG-012, a drug to treat renal function decline in patients with Alport syndrome, is moving into Phase 1 clinical trial, says its developer, Regulus Therapeutics. The company, based in La Jolla, Calif., expects this new trial to overcome the setback announced last November on its RG-012 Phase 2 study,…